




Q1 2021 Commercial Metrics

April 13, 2021

Commercial Metrics Overview

- Preliminary ZILRETTA® net sales of **\$24.6 million** in Q1 2021
- **4,417** accounts had purchased ZILRETTA, as of March 31, 2021; up from **4,248**, as of December 31, 2020
- **3,470** accounts had re-ordered ZILRETTA (79% of accounts that had purchased), as of March 31, 2021; up from **3,321** accounts that had re-ordered ZILRETTA (78% of accounts that had purchased) as of December 31, 2020
- As of March 31, 2021, Flexion had ~\$154 million in cash, cash equivalents and marketable securities and ~49.9 million shares outstanding


ZILRETTA Net Sales *Quarterly Since Launch*



Note: Flexion recognizes ZILRETTA sales upon receipt of product by specialty distributors and pharmacies.

Distribution of Accounts by ZILRETTA Purchases


Cumulative



Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics, and certain medical centers or hospitals) subsequently purchase ZILRETTA directly from these specialty distributors and the specialty pharmacy.

Distribution of ZILRETTA Purchases by Accounts


Cumulative



Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics, and certain medical centers or hospitals) subsequently purchase ZILRETTA directly from these specialty distributors and the specialty pharmacy.

ZILRETTA Purchases by New and Existing Accounts

Cumulative



Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics, and certain medical centers or hospitals) subsequently purchase ZILRETTA directly from these specialty distributors and the specialty pharmacy.



flexion

Transformative Medicine...
Where It Matters